The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to develop the molecule as a monotherapy. Led by AbbVie’s Humira, biologic TNF ...

However, the analyst contends that three of the four misses in today’s Phase 2 are “narrow – and will quite likely be ok” in a larger Phase 3 trial. The firm maintains an Outperform rating ...

Phase 2 will raise Northern Lights’ capacity from 1.5 million metric tons per annum (MMtpa) to over 5 MMtpa. The expansion will leverage existing onshore and offshore infrastructures and install ...

The registration deadline for Round 2 of the Prime Minister Internship Scheme 2025 has been extended to April 15, giving students and young professionals more time to apply. The scheme offers year ...

Construction on the U.S. 31 project in Franklin began on April 7 and will continue until summer 2028. JOHNSON COUNTY – Indiana Department of Transportation contractor Milestone Contractors is ...

Bioxodes has stopped enrolling people in a phase 2a stroke study after hitting the safety and efficacy endpoints, positioning the Belgian biotech to power into a potentially registrational trial.

Two agents targeting angiopoietin-like protein 3 safely lowered lipid levels in phase 2 trials. Solbinsiran and SHR-1918 will be further studied in patients with high lipid levels in phase 3 trials.

A Phase 2 trial demonstrated that the DPP-1 inhibitor HSK31858 significantly reduces acute exacerbations in non-cystic fibrosis bronchiectasis patients compared to placebo, with a 48% reduction at ...

The proposed Brookfield Reserve Phase 2 would replace an office building with 210 apartments and co-working space. An informational meeting for residents will be held April 29, with a Plan ...

The Phase 2 trial is a multi-center, single-arm, two-stage, open-label study designed to evaluate the safety and efficacy of MB-105 in patients with relapsed or refractory CD5-positive T-cell lymphoma ...

ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of ...